Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 11/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049831 | 0.86 | KDM4E (0.39) | KDM4EPDE4B | |
| SCHEMBL7472098 | 0.85 | KDM4E (0.41) | KDM4EPDE4B | |
| SCHEMBL6497602 | 0.78 | MEN1 (0.49) | KDM4EALDH1A1MAPTHTT | |
| SCHEMBL6497130 | 0.75 | NOTUM (0.48) | KDM4EDRD2DRD3PDE4BPDE4D | |
| SCHEMBL6498980 | 0.75 | NOTUM (0.48) | KDM4EDRD2DRD3PDE4BPDE4D | |
| SCHEMBL6496695 | 0.75 | DRD2 (0.49) | DRD2DRD3NOTUMALOX5 | |
| SCHEMBL6504244 | 0.71 | VNN1 (0.53) | DRD2DRD3PDE4DGRM5TP53 | |
| SCHEMBL7053331 | 0.71 | HCAR3 (0.40) | KDM4EALDH1A1MAPTTSHRDRD2 | |
| SCHEMBL7051584 | 0.70 | KDM4E (0.37) | KDM4EMAPT | |
| SCHEMBL7463190 | 0.70 | GCK (0.40) | ALDH1A1MAPTTSHRPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | KDM4E 945/4885ALDH1A1 1967/4885MAPT 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.